The Trump administration is set to unveil voluntary drug-pricing agreements with several midsized biotechnology firms, targeting discounts on outpatient medications for state Medicaid programs.
Under the proposed deals, participating companies will align the prices paid by state Medicaid programs with the lower prices charged in foreign markets. Participation by state Medicaid programs will be optional, and firms agreeing to the terms will receive exemptions from federal pilot programs that mandate similar discounts in Medicare. Some discussions also include relief from tariffs, according to sources familiar with the negotiations.
The administration has not disclosed which specific biotech companies will participate or the total number of firms involved. Savings estimates for the federal government and for low-income and disabled Medicaid patients remain uncertain, as do the potential financial impacts on drugmakers. The White House has emphasized progress in negotiating additional most-favored-nations deals to reduce drug costs for American patients, though officials caution that any agreements or announcements should be considered speculative until formally confirmed.
Medicaid already benefits from statutory discounts provided by drug manufacturers, and patients in the program typically incur minimal out-of-pocket costs for prescriptions. The administration’s initiative aims to extend these cost-saving measures while avoiding mandatory participation for states or companies.
